With regards to GM-CSF, a randomized phase III intergroup trial of nivolumab plus ipilimumab with or without sargramostim (EA6141) is currently recruiting subjects with advanced melanoma and should provide more guidance (NCT02339571). Here, CSF2 is linked to melanoma.